Navigation Links
Shire's New Product Portfolio Delivers Strong Quarterly Performance
Date:10/29/2008

PHILADELPHIA and DUBLIN, Ireland, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY) the global specialty biopharmaceutical company announces results for the three months to September 30, 2008.

Q3 2008 Financial Highlights

- Product sales up 31% to $713 million

- Product sales excluding ADDERALL XR(R) up 51% to $444 million

- New product sales(1) $276 million, 39% of product sales (2007:

22%)

- Total revenues up 28% to $779 million

- Non GAAP earnings(2) per ADS up 88% to $1.17 (2007: $0.62)

- US GAAP earnings(2) per ADS down 62% to $0.07 (2007: $0.19)

(1) New product sales comprise DAYTRANA(R), ELAPRASE(R), FIRAZYR(R), FOSRENOL(R), LIALDA(R) / MEZAVANT(R) and VYVANSE(R)

(2) Earnings from continuing operations

Angus Russell, Chief Executive Officer, commented:

"Shire had another very strong quarter across its business. Product sales were up 31% and Non GAAP earnings per ADS rose 88%, compared with the same period last year.

"Our new products continued to underpin this growth, generating revenues of $276 million, representing 39% of our total product sales and exceeding ADDERALL XR sales for the first time. The performance of ELAPRASE, VYVANSE, LIALDA and FOSRENOL ROW were particularly strong. This quarter FIRAZYR was made available in Germany and the UK. We remain confident that these products will continue to deliver strong growth, driven in part by our geographical expansion into the important emerging markets.

"Shire remains highly cash generative, supporting the investment we continue to make in developing our substantial pipeline of products and in expanding the reach of our existing portfolio. We have a robust balance sheet, good liquidity, and strong cash flow, with $279 million of cash flows from operating activities in the third quarter alone.

"We are in a strong position as we look ahead to the end of 2008 and beyond,
'/>"/>

SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
2. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
3. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
4. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
5. Consumers Looking to Sustainable Food Production to Feed Global Population
6. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
7. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
8. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
9. Ventria Expands Lactoferrin Production
10. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
11. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 28, 2015 , ... Riordan-McKenna Institute founders, stem ... that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic ... surgical knee wound. , The case involved a 78-year-old male, who presented with ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
(Date:8/27/2015)... YORK , August 27, 2015 ... enhancing image processing functions in the human vision system, announced ... point guard Chris Paul to develop ... players who want to improve their real-life on-court performance. ... the court, whether it is shooting a ball or blocking ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... Parker et al. entitled "Anti-Tumor Activity of Reovirus is ... Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment ... 28th American Society for Virology (ASV) Annual Meeting. The ...
... of 2009 (Excluding Technical, Plastics) at Prior ... - Sales Decline in the Cyclical Segments of Cosmetics and, ... In the first half of 2009, Gerresheimer AG achieved sales at the ... to sales growth for pharmaceutical packaging and systems,with which Gerresheimer today makes ...
... , SAN DIEGO, July 14 Amylin Pharmaceuticals, Inc. ... the second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ... lead the call. On the same date post-market, Amylin will release financial results ... The call will be webcast live through Amylin,s corporate Web site ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2Gerresheimer Holds its own in Difficult Environment 2Gerresheimer Holds its own in Difficult Environment 3Gerresheimer Holds its own in Difficult Environment 4Amylin Pharmaceuticals to Webcast Second Quarter Results 2
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... biochemical variations, or noise, leads to oscillations in gene ... debated for decades the relative importance of nature versus ... and now UCSD scientists report that noise could also ... In a paper in Proceedings of the National Academy ...
... EU-financed sleep research project is coordinated from FinlandIn ... network was establishedto investigate the causes and implications ... as from the social point of view. This ... effects of sleep restriction" will last for four ...
... cells is the work of machines that contain dozens of ... genomes, researchers now have a nearly complete "parts list" of ... all the pieces go. A new study by scientists at ... question for some of the smallest and trickiest components in ...
Cached Biology News:Phenotype is influenced by nature, nurture and noise 2Do the Europeans turn ill sitting up so late? 2Many needles, many haystacks 2